Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy - Full Text View

Sponsor:	University of Utah
Information provided by:	University of Utah
ClinicalTrials.gov Identifier:	NCT00528268

Purpose

In this single-center trial, we will evaluate the effects of NaPB on presymptomatic SMA type I (cohort 1)and presymptomatic SMA type II (cohort 2) infants. A variety of outcome measures will be performed at each study visit to follow the course of the disease. Total duration of the study for type I infants will be 18 months, for type II infants, 24 months.

Condition	Intervention	Phase
Spinal Muscular Atrophy	Drug: Sodium phenylbutyrate (NaPB)	Phase I Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title:	Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy

Resource links provided by NLM:

Genetics Home Reference related topics: spinal muscular atrophy

MedlinePlus related topics: Spinal Muscular Atrophy

Drug Information available for: Sodium phenylbutyrate

U.S. FDA Resources

Further study details as provided by University of Utah:

Primary Outcome Measures:

The study will assess the safety, tolerability and potential efficacy of sodium phenylbutyrate (NaPB) in presymptomatic infants genetically confirmed to have SMA. It will also determine selected pharmacokinetic parameters. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

The study will determine potential benefit of NaPB on lean body mass; overall motor function; potential cellular response to NaPB; and drug compliance. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	12
Study Start Date:	July 2007
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Cohort 1: Experimental Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies	Drug: Sodium phenylbutyrate (NaPB) The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
Cohort 2: Experimental Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies	Drug: Sodium phenylbutyrate (NaPB) The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.

Eligibility

Ages Eligible for Study:	up to 6 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Laboratory documentation of homozygous absence of SMN1 exon 7.
Confirmation of no more than 3 SMN2 copies for cohort 1; no more than 4 copies for cohort 2.
Family history of affected sibling with SMA type I for cohort 1 and SMA type II for cohort 2.
Age ≤ 3 months, cohort 1; Age ≤ 6 months, cohort 2.
Written informed consent of parents/guardian.
Laboratory results demonstrating normal values for age.

Exclusion Criteria:

-Evidence of hepatic insufficiency, renal insufficiency, edema with sodium retention, known seizure disorder, urea cycle disorder, cardiac arrhythmia, congenital heart defect, hypertension, significant central nervous system (CNS) impairment, or neurodegenerative or neuromuscular disease other than SMA.

History of allergy/sensitivity to sodium phenylbutyrate (NaPB).

Use of NaPB within 30 days of study entry.
Serious illness requiring hospitalization ≤ 14 days prior to study entry.
Use of medications intended for the treatment of SMA including riluzole, valproic acid, hydroxyurea, oral use of albuterol, NaPB, butyrate derivatives, creatine, growth hormone, anabolic steroids, probenecid, oral or parenteral use of corticosteroids at entry, or agents anticipated to increase or decrease muscle strength or agents with presumed histone deacetylase (HDAC) inhibition within 30 days prior to study entry.
Unwillingness to travel for study assessments.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528268

Contacts

Contact: Summer Davis	801-585-9717	sdavis@genetics.utah.edu
Contact: Benjamin Chisum, BS	801-585-9717	benjamin@genetics.utah.edu

Locations

United States, Utah
University of Utah	Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Sandra Reyna, MD 801-581-3551 sreyna@genetics.utah.edu
Contact: Summer Davis, BS 801-585-9717 sdavis@genetics.utah.edu

Sponsors and Collaborators

University of Utah

Investigators

Principal Investigator:

Kathryn Swoboda, MD

University of Utah

More Information

No publications provided

Responsible Party:	University of Utah School of Medicine ( Kathryn Swoboda, MD )
Study ID Numbers:	22183, 1-R01-HD054599-01
Study First Received:	September 10, 2007
Last Updated:	November 11, 2009
ClinicalTrials.gov Identifier:	NCT00528268 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by University of Utah:

Spinal Muscular Atrophy
SMA
Sodium Phenylbutyrate

Additional relevant MeSH terms:

Pathological Conditions, Anatomical
Neuromuscular Manifestations
Spinal Cord Diseases
Antineoplastic Agents
4-phenylbutyric acid
Nervous System Diseases
Central Nervous System Diseases
Neurodegenerative Diseases
Pharmacologic Actions

Signs and Symptoms
Neuromuscular Diseases
Muscular Atrophy, Spinal
Therapeutic Uses
Neurologic Manifestations
Atrophy
Motor Neuron Disease
Muscular Atrophy

ClinicalTrials.gov processed this record on February 08, 2010